APOE and Alzheimer disease: 48-week, double blind, randomized, placebo-controlled, parallel group, phase 3 studies, stratified for APOE ε4 status in subjects with mild-to-moderate probable AD. Outcome measures: ADAS-Cog, CDR-SB.